Lancet Oncol:质子束疗法或可取代传统放疗

2016-02-01 Mechront 译 MedSci原创

髓母细胞瘤是儿童中最常见的恶性脑肿瘤,且增长迅速,可以通过脑脊液扩散到不同位置。常规治疗有:手术、放疗、化疗。但副作用显著如:听力丧失、辐射导致器官毒性作用等。当患者在年轻的时候接受治疗,毒副作用会在以后的很长时间内均存在。新近提出的质子束疗法与传统放疗相比,具有很高的靶向性,此外还能降低周围组织损伤风险,减少毒副作用。近期麻省综合医院Torunn Yock博士及其团队进行了的一项发表在《柳叶刀肿

髓母细胞瘤是儿童中最常见的恶性脑肿瘤,且增长迅速,可以通过脑脊液扩散到不同位置。常规治疗有:手术、放疗、化疗。但副作用显著如:听力丧失、辐射导致器官毒性作用等。当患者在年轻的时候接受治疗,毒副作用会在以后的很长时间内均存在。

新近提出的质子束疗法与传统放疗相比,具有很高的靶向性,此外还能降低周围组织损伤风险,减少毒副作用。

近期麻省综合医院Torunn Yock博士及其团队进行了的一项发表在《柳叶刀肿瘤学》杂志上的研究表明,儿童脑肿瘤髓母细胞瘤的治疗中,质子束疗法比传统放疗更精确,且具有相似的安全性和生存率。

该研究纳入了59名3-21岁的患者,其中55名患者进行了肿瘤部分或完全切除术。所有的患者均接受化疗和质子束治疗。平均随访时间高达7年。

治疗后三年,12%的患者出现了严重的听力缺失,治疗后五年,该数值达16%。此外患者还出现了反应和语言理解问题,不过认知推理和记忆等仍正常。治疗后五年,55%的患者调节激素的神经内分泌系统出现了问题,生长激素是受影响的最常见激素。研究中没有发现心脏、肺、胃肠道等常见于放疗患者的毒副作用。

治疗后三年患者无进展生存率为83%,第五年该数据为80%。

研究结果表明,质子束疗法导致的毒副作用在可接受范围内,与传统放疗相比具有相似的生存预后,因此可以作为传统放疗的替代治疗方案。

原始出处:

Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study, Torunn I Yock, Beow Y Yeap, et al. The Lancet Oncology, doi: 10.1016/ S1470-2045(15)00167-9, published online 29 January 2016.

Proton beam therapy offers potential to treat childhood brain cancer with fewer severe side effects than conventional radiotherapy


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864754, encodeId=d0ad1864e542a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Feb 11 23:04:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828394, encodeId=00ae18283949b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 24 11:04:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64458, encodeId=b851644586f, content=新的放射治疗方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 19:47:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63773, encodeId=0d2663e73d4, content=有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63774, encodeId=b8e863e7445, content=起效?, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-11 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864754, encodeId=d0ad1864e542a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Feb 11 23:04:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828394, encodeId=00ae18283949b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 24 11:04:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64458, encodeId=b851644586f, content=新的放射治疗方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 19:47:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63773, encodeId=0d2663e73d4, content=有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63774, encodeId=b8e863e7445, content=起效?, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-03-24 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864754, encodeId=d0ad1864e542a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Feb 11 23:04:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828394, encodeId=00ae18283949b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 24 11:04:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64458, encodeId=b851644586f, content=新的放射治疗方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 19:47:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63773, encodeId=0d2663e73d4, content=有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63774, encodeId=b8e863e7445, content=起效?, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-16 mengli1984

    新的放射治疗方式

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864754, encodeId=d0ad1864e542a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Feb 11 23:04:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828394, encodeId=00ae18283949b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 24 11:04:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64458, encodeId=b851644586f, content=新的放射治疗方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 19:47:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63773, encodeId=0d2663e73d4, content=有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63774, encodeId=b8e863e7445, content=起效?, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-09 忠诚向上

    有用?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1864754, encodeId=d0ad1864e542a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Feb 11 23:04:00 CST 2016, time=2016-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828394, encodeId=00ae18283949b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Mar 24 11:04:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64458, encodeId=b851644586f, content=新的放射治疗方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/14/d0501100fdfe783cab0715811e01c133.jpg, createdBy=51ed1602754, createdName=mengli1984, createdTime=Tue Feb 16 19:47:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63773, encodeId=0d2663e73d4, content=有用?, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63774, encodeId=b8e863e7445, content=起效?, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Feb 09 08:02:00 CST 2016, time=2016-02-09, status=1, ipAttribution=)]
    2016-02-09 忠诚向上

    起效?

    0

相关资讯

梅奥:胰腺癌术后放疗可显著降低肿瘤复发

梅奥诊所癌症中心的放射肿瘤学家Christopher Hallemeier博士发现,对胰腺癌术后患者进行放疗可降低癌症复发率,就像化疗一样,是胰腺癌患者的重要治疗方式。该研究共纳入458名胰腺癌术后患者,其中378名患者术后接受化疗和放疗,80名患者术后只接受化疗。研究数据显示,诊断后5年内,进行化疗和放疗的患者中有80%的人放疗部位、肿瘤床和淋巴结没有发现复发,而术后仅化疗组该数据为68%。此外

Cancer Res:放疗激活新途径 让前列腺癌治疗更有效

        最近一项研究发现两种常用的前列腺癌治疗方法在分子层面存在重要联系,这一发现或可帮助病人更加轻松地杀死前列腺癌细胞。科学家正在研发可以利用这种关联进行癌细胞杀伤的药物,未来将进行临床研究检测这一发现是否能够帮助治疗前列腺癌。   文章作者还表示,这项发现还可能帮助医生更好地确定哪种治疗方法对病人最有利,同时可能对其他类型癌

Medicine:头颈部肿瘤患者放射治疗时,警惕发生痴呆

头颈部癌患者进行手术、放疗、化疗(CT)。以前观察到这些患者存在颈动脉损伤和神经毒性。这项研究估计头部和颈部癌症患者不同治疗后,老年痴呆症发生的风险。分析台湾的国家健康保险索赔数据库和癌症登记数据库中的数据。研究包括2002年1月1日至2010年12月31日进行治疗的头颈部癌患者。随访时间从指数日期至2012年12月31日。纳入标准为头颈部肿瘤;年龄>20岁;并接受手术、化疗、并行化疗或手术辅助治

JCO:小细胞肺癌患者手术切除后有必要接受辅助化疗吗?

 在过去的二十年中,许多临床研究表明接受手术的一期小细胞肺癌患者的5年生存率大约为40%-60%。美国国家综合癌症网络推荐手术患者接受辅助化疗。但是,对于此类患者如何选择化疗方案缺乏相应的数据,用于此类人群的辅助化疗的作用仍未被完全阐明。目前除了少数研究来评价二期小细胞肺癌患者手术后辅助化疗的结局,没有其他的研究,无论是前瞻性还是回顾性的研究来评价辅助化疗的作用。因此研究人员分析了美国国

BMC Cancer:晚期鼻咽癌治疗方案比较

研究者对经调强放疗(IMRT)治疗后的局部区域晚期鼻咽癌患者进行了一项研究,比较以下几种治疗方式的生存结局和急性毒性作用:同步放化疗(CCRT)、诱导化疗+放射治疗(IC)+(RT)、IC +CCRT。研究者纳入了2009-2012年间经调强放疗(IMRT)治疗的 III-IVB期鼻咽癌患者。诱导方案包括 PF(顺铂、氟尿嘧啶)和TP(多西紫杉醇、顺铂),每3周进行一次诱导治疗,持续2-3个周期;

BMC Cancer:AFP可作为肝癌放疗后预测指标

研究者进行了一向研究,评估小的肝细胞性肝癌(HCC)患者进行立体定向放射治疗(SBRT)后,甲胎蛋白(AFP)作为预后指标的意义。该回顾性研究纳入了165名原发或复发HCC患者,均进行了SBRT,经筛查后选择了77名符合以下纳入标准的患者:1)SBRT术前AFP > 20 ng/mL ;2)SBRT术后三个月内复查AFP。使用倾向得分匹配分析使潜在混杂因素最小化。正常AFP值定义为其含量 ≤